
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About
Vera Therapeutics Inc (VERA)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: VERA (2-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $63.36
1 Year Target Price $63.36
9 | Strong Buy |
4 | Buy |
1 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 371.66% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.34B USD | Price to earnings Ratio - | 1Y Target Price 63.36 |
Price to earnings Ratio - | 1Y Target Price 63.36 | ||
Volume (30-day avg) 14 | Beta 1.19 | 52 Weeks Range 18.53 - 51.61 | Updated Date 08/3/2025 |
52 Weeks Range 18.53 - 51.61 | Updated Date 08/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3 |
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.8214 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -23.46% | Return on Equity (TTM) -39.49% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 800699610 | Price to Sales(TTM) - |
Enterprise Value 800699610 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.6 | Shares Outstanding 63774200 | Shares Floating 46894414 |
Shares Outstanding 63774200 | Shares Floating 46894414 | ||
Percent Insiders 3.97 | Percent Institutions 111.53 |
Upturn AI SWOT
Vera Therapeutics Inc
Company Overview
History and Background
Vera Therapeutics, Inc. is a late-stage biotechnology company focused on developing treatments for serious immunological diseases. It was founded in 2016 and went public in 2021. The company's initial focus was on oncology before pivoting to immunology.
Core Business Areas
- Atacicept Development: Vera's primary focus is the development of atacicept for IgA nephropathy (IgAN) and other B cell-mediated autoimmune diseases. Atacicept is a fusion protein designed to reduce levels of BAFF and APRIL, two cytokines that contribute to B-cell survival and antibody production.
Leadership and Structure
The leadership team includes key executives with experience in drug development and commercialization. The company has a board of directors providing strategic oversight.
Top Products and Market Share
Key Offerings
- Atacicept (VRX-311): Atacicept is Vera's lead drug candidate, currently in Phase 3 clinical development for IgA nephropathy (IgAN). Market share is not applicable as the drug is not yet approved. Competitors include Calliditas Therapeutics (TARPEYO) and Travere Therapeutics (FILSPARI).
Market Dynamics
Industry Overview
The biotechnology industry, particularly in the autoimmune disease space, is competitive and rapidly evolving. The demand for novel therapies is high, but regulatory hurdles and clinical trial risks remain significant.
Positioning
Vera Therapeutics is positioned as a late-stage biotechnology company with a promising therapeutic candidate targeting a specific disease mechanism in IgAN. Competitive advantages lie in the drug's novel mechanism of action and the unmet medical need in IgAN.
Total Addressable Market (TAM)
The estimated global IgAN market is expected to reach billions of dollars. Vera is attempting to capture a significant portion of this TAM with its Atacicept therapy.
Upturn SWOT Analysis
Strengths
- Late-stage clinical program (Phase 3)
- Novel mechanism of action
- Experienced management team
- Strong financial backing
Weaknesses
- Single product focus (Atacicept)
- Clinical trial risk
- Dependence on regulatory approval
- Limited commercial infrastructure
Opportunities
- Expansion into other B-cell mediated autoimmune diseases
- Potential for partnership or acquisition
- Positive clinical trial results
- Favorable regulatory environment
Threats
- Clinical trial failure
- Regulatory delays or rejection
- Competition from other therapies
- Patent challenges
Competitors and Market Share
Key Competitors
- KDNY
- TRVC
Competitive Landscape
Vera faces competition from established players with approved therapies for IgAN. Vera's advantage lies in Atacicept's unique mechanism of action, potentially offering a different treatment option for patients. However, its lack of an approved product puts it at a disadvantage compared to companies with established market presence.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily reflected in the advancement of Atacicept through clinical trials.
Future Projections: Future growth is highly dependent on the success of Atacicept's Phase 3 trial and subsequent regulatory approval. Analyst estimates vary based on their assessment of the drug's potential.
Recent Initiatives: Recent initiatives include the commencement and continuation of the ORIGIN3 Phase 3 clinical trial for Atacicept in IgAN.
Summary
Vera Therapeutics is a clinical-stage biotech company focused on developing Atacicept for IgAN. Its strength lies in its Phase 3 program and novel mechanism of action. A key risk is the potential for clinical trial failure. Positive clinical data is critical for the company to realize its potential.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on thorough research and consultation with a qualified financial advisor. Market data is dynamic and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Vera Therapeutics Inc
Exchange NASDAQ | Headquaters Brisbane, CA, United States | ||
IPO Launch date 2021-05-14 | Founder, President, CEO & Director Dr. Marshall W. Fordyce M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 152 | Website https://veratx.com |
Full time employees 152 | Website https://veratx.com |
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with serious immunological diseases. The company's lead product candidate consists of atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN). It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.